(Q85906649)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Georges Deschenes

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Helene Munyentwali

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Khedidja Bouachi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Philippe Remy

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Philippe Lang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Rachid Mojaat

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Pierre M Ronco

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Emmanuelle M Plaisier

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Karine Y Dahan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

16 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

511-516

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23325085%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/ki.2012.444

22 February 2020

exact match

0 references

cites work

Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Steroid-sensitive nephrotic syndrome: from childhood to adulthood

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Rituximab for idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Rituximab treatment of idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Nephrotic syndrome and rituximab: facts and perspectives

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Rituximab efficiency in children with steroid-dependent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Rituximab in adult patients with immunosuppressive-dependent minimal change disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Transmission of glomerular permeability factor from a mother to her child

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Pathogenesis of lipoid nephrosis: a disorder of T-cell function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Rituximab and minimal change nephrotic syndrome: a therapeutic option

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

New insights into the pathophysiology of idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021

Rituximab for refractory cases of childhood nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.444

7 January 2021